Hematology and Oncology Department, Dongzhimen Hospital, Beijing University of Chinese Medicine, Hai Yun Cang on the 5th Zip, Dongcheng District, Beijing, China.
Pfizer Inc, Hospital BU, 23 East 42nd Street, New York, NY, 10017, USA.
BMC Infect Dis. 2022 Feb 14;22(1):154. doi: 10.1186/s12879-022-07115-w.
Invasive mucormycosis (IM) is a rare and often life-threatening fungal infection, for which clinical and epidemiological understanding is lacking. Electronic health record (EHR) data can be utilized to elucidate large populations of patients with IM to address this unmet need. This study aimed to descriptively assess data on patients with IM using the Optum® EHR dataset.
US patient data from the Optum® deidentified EHR dataset (2007-2019) were analyzed to identify patients with IM. Patients with hematologic malignancies (HM), at high risk of IM, were selected and sorted by IM diagnosis (ICD9 117.7; ICD10 B46). Demographics, comorbidities/other diagnoses, and treatments were analyzed in patients with IM.
In total, 1133 patients with HM and IM were identified. Most were between 40 and 64 years of age, Caucasian, and from the Midwest. Essential primary hypertension (50.31%) was the most common comorbidity. Of the 1133 patients, only 33.72% were prescribed an antifungal treatment. The most common antifungal treatments were fluconazole (24.27%) and posaconazole (16.33%), which may have been prophylactic, and any AmB (15.62%).
A large population of patients with IM were identified, highlighting the potential of analyzing EHR data to investigate epidemiology, diagnosis, and the treatment of apparently rare diseases.
侵袭性毛霉病(IM)是一种罕见且通常危及生命的真菌感染,目前对其临床和流行病学认识不足。电子健康记录(EHR)数据可用于阐明大量 IM 患者的情况,以满足这一未满足的需求。本研究旨在使用 Optum®EHR 数据集描述性评估 IM 患者的数据。
分析来自 Optum®匿名 EHR 数据集(2007-2019 年)的美国患者数据,以确定 IM 患者。选择患有血液恶性肿瘤(HM)且有发生 IM 高风险的患者,并按 IM 诊断(ICD9 117.7;ICD10 B46)进行分类。分析 IM 患者的人口统计学、合并症/其他诊断和治疗情况。
共确定了 1133 例 HM 合并 IM 患者。他们大多年龄在 40 至 64 岁之间,白种人,来自中西部地区。原发性高血压(50.31%)是最常见的合并症。在 1133 例患者中,只有 33.72%接受了抗真菌治疗。最常用的抗真菌治疗药物是氟康唑(24.27%)和泊沙康唑(16.33%),可能是预防性用药,还有任何两性霉素 B(15.62%)。
确定了大量 IM 患者,突出了分析 EHR 数据以调查罕见疾病的流行病学、诊断和治疗的潜力。